In a report released today, Ed Arce from H.C. Wainwright maintained Pliant Therapeutics (PLRX – Research Report) to a Buy, with a price target of $52.00. Ed Arce’s Buy rating for Pliant Therapeutics ...

Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexotegrast was successful. The phase IIa INTEGRIS-PSC ...

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic ...

SAN FRANCISCO--(BUSINESS WIRE)--Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective ...

TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, ...

Tsukuba, Japan—Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammatory disease characterized by fibrosis and bile duct stricturing, which ultimately leads to cirrhosis and liver ...

Research collaboration: International PSC Study Group (IPSCSG) is a research collaboration whose article contributions are accrued to its participating partner institutions. Identify research insights ...